Acute myocardial infarction in patients with heart failure
Authors:
Z. Pozdíšek
Authors‘ workplace:
I. interní klinika FN a LF MU Brno
Published in:
Kardiol Rev Int Med 2010, 12(3): 115-117
Overview
Despite advances in treatment, heart failure is associated with poor prognosis and is among the leading causes of hospitalization in developed countries. The incidence of acute myocardial infarction is relatively low considering the high prevalence of ischemic heart disease of up to 70% in these patients [1,2]. More strict definition of myocardial infarction in clinical trials compared to routine clinical practice is one of the possible explanations but other reasons are also to be considered.
Keywords:
heart failure – myocardial infarction – prognosis
Sources
1. Špinar J, Hradec J, Meluzín J. Doporučení pro diagnostiku a léčbu chronického srdečního selhání ČKS 2006 (1). Cor Vasa 2007; 49: K5–K34.
2. Špinar J, Hradec J, Meluzín J. Doporučení pro diagnostiku a léčbu chronického srdečního selhání ČKS 2006 (2). Cor Vasa 2007; 49 (Suppl.): 75–104.
3. Uretsky BF, Thygesen K, Armstrong PW et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation 2000; 102: 611–616.
4. CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet 1999; 353: 9–13.
5. O´Connor CM, Gottlieb S, Bourque JM et al. Impact of Nanfatal Myocardial Infarction on Outcomes in Patients With Advandced Heart Failure and th Effect of Bucindolol Therapy. Am J Cardiol 2005; 95: 558–564.
6. Khand AU, Gemmell I, Randin AC et al. Clinical events leading to the progression of heart failure: new insights from a national database of hospital discharges. Eur Heart J 2001; 22: 153–164.
7. Fox KM. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–788.
8. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145–153.
9. Yusuf S, Pepine CJ, Garces C et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992; 340: 1173–1178.
10. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993; 342: 821–828.
11. Køber L, Torp-Pedersen C, Carlsen JE et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333: 1670–1676.
12. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001; 357: 1385–1390.
13. Jánosi A, Ghali JK, Herlitz J et al. MERIT-HF Study Group. Metoprolol CR/XL in postmyocardial infarction patients with chronic heart failure: experiences from MERIT-HF. Am Heart J 2003; 146: 721–728.
14. Packer J, Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1349–1355.
15. A randomized trial of betablockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation 1994; 90: 1765–1773.
16. Flather MD, Shibata MC, Coats AJS et al. SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26: 215–225.
17. Kjekshus J, Apetrei E, Barrios V et al. CORONA Group. Rosuvastatin in Older Patients with Systolic Heart Failure. N Engl J Med 2007; 357: 2248–2261.
18. Gissi-HF Investigators. Tavazzi L, Maggioni AP, Marchioli R et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1231–1239.
Labels
Paediatric cardiology Internal medicine Cardiac surgery CardiologyArticle was published in
Cardiology Review
2010 Issue 3
Most read in this issue
- Contemporary methods to determine glomerular filtration and their clinical relevance
- Pharmacoeconomics for physicians in clinical practice
- Risk factors of atrial fibrillation
- Does ischemic heart disease differ in men and women?